文献速递乳腺癌

帕妥珠单抗联合曲妥珠单抗治疗转移性乳腺癌的成本效果分析

Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.
PubMed 文献 · JAMA Oncol · 2022-01-01

在加拿大安大略省开展基于人群的回顾性经济学评价,纳入1158例接受一线治疗的转移性乳腺癌患者,匹配579对比较帕妥珠单抗联合曲妥珠单抗及化疗与曲妥珠单抗及化疗。帕妥珠单抗组增加0.61生命年和0.44质量调整生命年,增量成本192139加元,增量成本效果比为每生命年316203加元和每质量调整生命年436679加元。作者认为帕妥珠单抗可能增加生存但即使价格降至零也不符合常规成本效果阈值。

要点

  • 帕妥珠单抗联合方案较对照增加0.61生命年和0.44质量调整生命年,增量成本192139加元。
  • 增量成本效果比为每生命年316203加元和每质量调整生命年436679加元。
  • 帕妥珠单抗价格降低100%时,每质量调整生命年增量成本效果比为174027加元。

核心结论

  • 基于人群的研究结果提示帕妥珠单抗可能延长转移性乳腺癌患者生存,但即使帕妥珠单抗价格降低100%,按常规阈值仍不具成本效果。

研究设计与样本

  • 加拿大安大略省基于人群的回顾性经济学评价,纳入2008年1月1日至2018年3月31日接受一线治疗的转移性乳腺癌患者,从安大略癌症登记处识别并链接新药资助计划数据库,N=1158。
  • 患者自治疗开始随访至5年,最长随访至2019年3月31日;从公共支付方视角,基于行政数据估算5年时间horizon的成本效果,校正删失并贴现1.5%。
  • 比较2013年11月25日公共资助后帕妥珠单抗联合曲妥珠单抗及化疗与资助前曲妥珠单抗及化疗,纳入579对匹配患者。

主要发现

  • 匹配研究队列平均(SD)年龄58(12.97)岁,女性1151例(99.4%)。
  • 帕妥珠单抗组增加0.61生命年和0.44质量调整生命年,增量成本192139加元(所有成本为加拿大元)。
  • 增量成本效果比为每生命年316203加元和每质量调整生命年436679加元。
  • 成本构成中帕妥珠单抗占60%,门诊癌症治疗实施占24%,曲妥珠单抗占15%。
  • 帕妥珠单抗价格降低100%时,每质量调整生命年增量成本效果比为174027加元;帕妥珠单抗和曲妥珠单抗价格均降低超过71%时,每质量调整生命年增量成本效果比降至100000加元以下。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The initial assessment of pertuzumab use for treatment of metastatic breast cancer by health technology assessment agencies suggested that pertuzumab was not cost-effective. In Ontario, Canada, pertuzumab became funded in November 2013 based on the substantial clinical benefit. To date, there is a paucity of analysis of pertuzumab using real-world data for cost-effectiveness. OBJECTIVE: To assess the cost-effectiveness of pertuzumab, trastuzumab, and chemotherapy vs trastuzumab and chemotherapy for patients with metastatic breast cancer. DESIGN, SETTING, AND PARTICIPANTS: A population-based retrospective economic evaluation was conducted in Ontario, Canada. Patients who received first-line treatments for metastatic breast cancer from January 1, 2008, to March 31, 2018, were identified. Patients were followed up from the start of treatment up to 5 years, with maximum follow-up to March 31, 2019. Patients were identified from the Ontario Cancer Registry and linked to the New Drug Funding Program database to identify receipt of first-line treatment (N = 1158). INTERVENTIONS: Treatment with pertuzumab, trastuzumab, and chemotherapy after public funding (November 25, 2013) compared with treatment with trastuzumab and chemotherapy before funding. MAIN OUTCOMES AND MEASURES: Cost-effectiveness, from a public payer perspective, was estimated from administrative data with a 5-year time horizon, adjusted for censoring, and discounted (1.5%). Incremental cost-effectiveness ratios for life-years gained and quality-adjusted life year (QALY) with bootstrapped 95% CIs were calculated. Sensitivity analysis with price reduction of pertuzumab alone or in combination with trastuzumab was conducted. RESULTS: A total of 579 pairs of matched patients receiving pertuzumab and controls were included. The mean (SD) age of the matched study cohort was 58 (12.97) years; 1151 were women (99.4%). Pertuzumab resulted in 0.61 life-years gained and 0.44 QALYs gained at an incremental cost of $192 139 (all costs measured in Canadian dollar values, CAD) with an incremental cost-effectiveness ratio of $316 203 per life-year gained and $436 679 per QALY. The main factors associated with cost included the cost of pertuzumab (60%), outpatient cancer treatment delivery (24%), and trastuzumab (15%). With 100% price reduction of pertuzumab, the incremental cost-effectiveness ratio was $174 027 per QALY. When the price of pertuzumab and trastuzumab were both reduced by more than 71%, the incremental cost-effectiveness ratio decreased below $100 000 per QALY. CONCLUSIONS AND RELEVANCE: The findings of this population-based study suggest that pertuzumab may increase survival for patients with metastatic breast cancer but would not be considered cost-effective, even after 100% price reduction, under conventional thresholds.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Dai WF, Beca JM, Nagamuthu C, et al. Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer. JAMA Oncol. 2022. PMID: 35201264. doi:10.1001/jamaoncol.2021.8049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。